Recombinant Human Angiopoietin-like 4 / ANGPTL4 (166-406) Protein, His tag, 100 µg

Background
Angiopoietin-related protein 4 (ANGPTL4) is also known as Hepatic fibrinogen / angiopoietin - related protein (HFARP), ARP4, PGAR. ANGPTL4 contains one fibrinogen C-terminal domain. ANGPTL4 is a homooligomer , and the homooligomer undergoes proteolytic processing to release its carboxyl fibrinogen-like domain, which circulates as a monomer. The homooligomer unprocessed form is able to interact with the extracellular matrix. ANGPTL4 may act as a regulator of angiogenesis and modulate tumorigenesis. ANGPTL4 inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. ANGPTL4 may exert a protective function on endothelial cells through an endocrine action.

Source
Recombinant Human Angiopoietin-like 4 (166-406), His Tag (AN4-H5243) is expressed from human 293 cells (HEK293). It contains AA Pro 166 - Ser 406 (Accession # Q9BY76-1).
Predicted N-terminus: His

Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 27.9 kDa. The protein migrates as 31-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM MOPS, 100 mM NaCl, pH7.2. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Menstrual blood-derived stromal cells: insights into their secretome in acute hypoxia conditions"
de Pedro, Pulido, Álvarez et al
Mol Med (2023) 29 (1), 48
(2) "A multi-purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo-controlled, single-ascending dose study in adults"
Fukuhara, Furihata, Matsuoka et al
Clin Transl Sci (2023)
J Neurochem (2021)
(3) "Linoleic acid-induced ANGPTL4 inhibits C2C12 skeletal muscle differentiation by suppressing Wnt/β-catenin"
Son, Lorenz, Paton
J Nutr Biochem (2023)
Showing 1-3 of 1223 papers.